Inappropriate sexual behaviors in cognitively impaired older individuals

American Journal Geriatric Pharmacotherapy

Volumn 6, Issue 5, 2008, Pages 269-288

  Guay, David R P ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

aged; cyproterone acetate; estrogens; hypersexuality; leuprolide; medroxyprogesterone acetate; selective serotonin reuptake inhibitors; sexual behaviors; tricyclic antidepressants

Indexed keywords

ANTIANDROGEN; ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; BICALUTAMIDE; CARBAMAZEPINE; CIMETIDINE; CYPROTERONE ACETATE; DIETHYLSTILBESTROL; DOPAMINE RECEPTOR STIMULATING AGENT; ESTRADIOL; ESTROGEN; ETHINYLESTRADIOL; FLUTAMIDE; GESTAGEN; GONADORELIN AGONIST; HALOPERIDOL; KETOCONAZOLE; LEUPRORELIN; MEDROXYPROGESTERONE ACETATE; NEUROLEPTIC AGENT; PAROXETINE; PSYCHOSTIMULANT AGENT; SEROTONIN AGONIST; SEROTONIN UPTAKE INHIBITOR; SPIRONOLACTONE; THIORIDAZINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIPTORELIN; UNINDEXED DRUG;

ADRENAL DISEASE; AGGRESSION; AGITATION; ALZHEIMER DISEASE; ARTHRALGIA; ARTICLE; BEHAVIOR DISORDER; BONE DENSITY; CASE STUDY; CLINICAL TRIAL; COGNITIVE DEFECT; DEPRESSION; DIABETES MELLITUS; DIARRHEA; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG EXCRETION; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG MONITORING; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPEPSIA; FACE EDEMA; FOOT EDEMA; GALLSTONE; GERIATRIC CARE; GYNECOMASTIA; HAIR DISEASE; HIRSUTISM; HUMAN; HYPERSEXUALITY; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INJECTION SITE PAIN; LOW DRUG DOSE; MALAISE; MEDICAL ETHICS; MEDLINE; MONOTHERAPY; MULTIINFARCT DEMENTIA; MUSCLE CRAMP; MYALGIA; NAUSEA; NONHUMAN; OSTEOPENIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOSIS; RECEPTOR BLOCKING; REMISSION; RETINA VEIN OCCLUSION; RISK ASSESSMENT; RISK FACTOR; SEXUAL BEHAVIOR; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP DISORDER; TRANSVESTISM; TREATMENT DURATION; VENOUS THROMBOEMBOLISM; WEIGHT GAIN; WEIGHT REDUCTION;

AGED; COGNITION DISORDERS; FEMALE; HUMANS; MALE; SEXUAL BEHAVIOR; TIME FACTORS;

EID: 58349122506     PISSN: 15435946     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjopharm.2008.12.004     Document Type: Article

References (102)

1. Lyketsos C.G., Steinberg M., Tschanz J.T., et al. Mental and behavioral disturbances in dementia: Findings from the Cache County Study on Memory in Aging. Am J Psychiatry 157 (2000) 708-714
2. Margallo-Lana M., Swann A., O'Brien J., et al. Prevalence and pharmacological management of behavioural and psychological symptoms amongst dementia sufferers living in care environments. Int J Geriatr Psychiatry 16 (2001) 39-44
3. Finkel S.I., Costa e Silva J., Cohen G., et al. Behavioral and psychological signs and symptoms of dementia: A consensus statement on current knowledge and implications for research and treatment. Int Psychogeriatr 8 Suppl 3 (1996) 497-500
4. Steele C., Rovner B., Chase G.A., and Folstein M. Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease. Am J Psychiatry 147 (1990) 1049-1051
5. O'Donnell B.F., Drachman D.A., Barnes H.J., et al. Incontinence and troublesome behaviors predict institutionalization in dementia. J Geriatr Psychiatry Neurol 5 (1992) 45-52
6. Marsiglio W., and Donnelly D. Sexual relations in later life: A national study of married persons. J Gerontol 46 (1991) S338-S344
7. Comfort A., and Dial L.K. Sexuality and aging: An overview. Clin Geriatr Med 7 (1991) 1-7
8. Johnson C., Knight C., and Alderman N. Challenges associated with the definition and assessment of inappropriate sexual behaviour amongst individuals with an acquired neurological impairment. Brain Inj 20 (2006) 687-693
9. Kuhn D.R., Greiner D., and Arseneau L. Addressing hypersexuality in Alzheimer's disease. J Gerontol Nurs 24 (1998) 44-50
10. Higgins A., Barker P., and Begley C.M. Hypersexuality and dementia: Dealing with inappropriate sexual expression. Br J Nurs 13 (2004-2005) 1330-1334
11. Wright L.K. Alzheimer's Disease and Marriage (1993), Sage, Newbury Park, Calif
12. Derouesné C., Guigot J., Chermat V., et al. Sexual behavioral changes in Alzheimer disease. Alzheimer Dis Assoc Disord 10 (1996) 86-92
13. Tsai S.J., Hwang J.P., Yang C.H., et al. Inappropriate sexual behaviors in dementia: A preliminary report. Alzheimer Dis Assoc Disord 13 (1999) 60-62
14. Alagiakrishnan K., Lim D., Brahim A., et al. Sexually inappropriate behaviour in demented elderly people. Postgrad Med J 81 (2005) 463-466
15. Zeiss A.M., Davies H.D., and Tinklenberg J.R. An observational study of sexual behavior in demented male patients. J Gerontol A Biol Sci Med Sci 51 (1996) M325-M329
16. Lesser J.M., Hughes S.V., Jemelka J.R., and Griffith J. Sexually inappropriate behaviors. Assessment necessitates careful medical and psychological evaluation and sensitivity. Geriatrics 60 (2005) 34 36-37
17. Sloane P. Sexual behavior in residents with dementia. Guidelines explain how to respond. Contemp Longterm Care 16 (1993) 66 69, 108
18. Arnulf I., Zeitzer J.M., File J., et al. Kleine-Levin syndrome: A systematic review of 186 cases in the literature. Brain 128 (2005) 2763-2776
19. Goscínski I., Kwiatkowski S., Polak J., and Orlowiejska M. The Kluver-Bucy syndrome. Acta Neurochir (Wien) 139 (1997) 303-306
20. Goscínski I., Kwiatkowski S., Polak J., et al. The Kluver-Bucy syndrome. J Neurosurg Sci 41 (1997) 269-272
21. Cummings J.L. Behavioral and psychiatric symptoms associated with Huntington's disease. Adv Neurol 65 (1995) 179-186
22. Miller B.L., Cummings J.L., McIntyre H., et al. Hypersexuality or altered sexual preference following brain injury. J Neurol Neurosurg Psychiatry 49 (1986) 867-873
23. Klos K.J., Bower J.H., Josephs K.A., et al. Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy. Parkinsonism Relat Disord 11 (2005) 381-386
24. Uitti R.J., Tanner C.M., Rajput A.H., et al. Hypersexuality with antiparkinsonian therapy. Clin Neuropharmacol 12 (1989) 375-383
25. Markham C.H., Treciokas L.J., and Diamond S.G. Parkinson's disease and levodopa. A five-year follow-up and review. West J Med 121 (1974) 188-206
26. Cannas A., Solla P., Floris G., et al. Hypersexual behaviour, frotteurism, and delusional jealousy in a young parkinsonian patient during dopaminergic therapy with pergolide: A rare case of iatrogenic paraphilia. Prog Neuropsychopharmacol Biol Psychiatry 30 (2006) 1539-1541
27. Lam M.H., Fong S.Y., and Wing Y.K. Sexual disinhibition in schizophrenia possibly induced by risperidone and quetiapine. Psychiatry Clin Neurosci 61 (2007) 333 Letter
28. Nickel M., Moleda D., Loew T., et al. Cabergoline treatment in men with psychogenic erectile dysfunction: A randomized, double-blind, placebo-controlled study. Int J Impot Res 19 (2007) 104-107
29. Wittstock M., Benecke R., and Dressler D. Cabergoline can increase penile erections and libido. Neurology 58 (2002) 831 Letter
30. Fernandez H.H., and Durso R. Clozapine for dopaminergicinduced paraphilias in Parkinson's disease. Mov Disord 13 (1998) 597-598
31. Schober J.M., and Pfaff D. The neurophysiology of sexual arousal. Best Prac Res Clin Endocrinol Metab 21 (2007) 445-461
32. Kafka M.P. The monoamine hypothesis for the pathophysiology of paraphilic disorders: An update. Ann NY Acad Sci 989 (2003) 86-94
33. Saleh F.M., and Berlin F.S. Sex hormones, neurotransmitters, and psychopharmacological treatments in men with paraphilic disorders. J Child Sex Abus 12 (2003) 233-253
34. Loosen P.T., Purdon S.E., and Pavlou S.N. Effects on behavior of modulation of gonadal function in men with gonadotropin-releasing hormone antagonists. Am J Psychiatry 151 (1994) 271-273
35. Guay DR. Drug treatment of paraphilias. Clin Ther. In press.
36. Neumann F., and Graf K. Discovery, development, mode of action, and clinical use of cyproterone acetate. J Int Med Res 3 Suppl 4 (1975) 1-9
37. Stitch S.R. Steroid chemistry. J Int Med Res 3 Suppl 4 (1975) 10-12
38. Neumann F., von Berswordt-Wallrabe R., Elger W., et al. Aspects of androgen-dependent events as studied by antiandrogens. Rec Prog Hormone Res 26 (1970) 337-410
39. Bohl C.E., Wu Z., Miller D.D., et al. Crystal structure of the T877A human androgen receptor ligand-binding domain complexed to cyproterone acetate provides insight for ligand-induced conformational changes and structure-based drug design. J Biol Chem 282 (2007) 13648-13655
40. Vosbeck K., and Keller P.J. The influence of antiandrogens on the excretion of FSH, LH, and 17-ketosteroids in males. Hormone Metab Res 3 (1971) 273-276
41. Laschet U., and Laschet L. Antiandrogens in the treatment of sexual deviations of men. J Steroid Biochem 6 (1975) 821-826
42. Anonymous. Cyproterone acetate, medroxyprogesterone acetate, leuprolide, triptorelin. Martindale: The Complete Drug Reference (2007), Pharmaceutical Press, London, UK 1644-1645 1657-1658, 1904-1906, 1920-1921
43. Jurzyk R.S., Spielvogel R.L., and Rose L.I. Antiandrogens in the treatment of acne and hirsutism. Am Fam Physician 45 (1992) 1803-1806
44. Jungers P., Kuttenn F., Liote F., et al. Hormone modulation in systemic lupus erythematosus. Preliminary clinical and hormone results with cyproterone acetate. Arthritis Rheum 28 (1985) 1243-1250
45. Eriksson T., and Eriksson M. Irradiation therapy prevents gynecomastia in sex offenders treated with antiandrogens. J Clin Psychiatry 59 (1998) 432-433
46. Heinemann L., Will-Shahab L., van Kesteren P., et al. Safety of cyproterone acetate: Report of active surveillance. Pharmacoepidemiol Drug Saf 6 (1997) 169-178
47. Miguel M., Soler A., Vaqué A., et al. Suspected cross-hepatotoxicity of flutamide and cyproterone acetate. Liver Int 27 (2007) 1144-1147
48. Seaman H.E., Langley S.E., Farmer R.D., and de Vries C.S. Venous thromboembolism and cyproterone acetate in men with prostate cancer: A study using the General Practice Research Database. BJU Int 99 (2007) 1398-1403
49. Grasswick L.J., and Bradford J.M. Osteoporosis associated with the treatment of paraphilias: A clinical review of seven case reports. J Forensic Sci 48 (2003) 849-855
50. Unger H.R. Cyproterone and hypersexuality. N Z Med J 86 (1977) 39-40
51. Depo-subQ provera 104 (medroxyprogesterone acetate injectable suspension 104 mg/0.65 mL) [package insert] (2004), Pharmacia & Upjohn, New York, NY
52. Provera (medroxyprogesterone) [package insert] (1998), Pharmacia & Upjohn, Kalamazoo, Mich
53. Depo-Provera Contraceptive Injection (medroxyprogesterone acetate injectable suspension) [package insert] (2004), Pharmacia & Upjohn, New York, NY
54. Løber J., Mouridsen H.T., Salimtschik M., and Johansson E. Pharmacokinetics of medroxyprogesterone acetate administered by oral and intramuscular route. Acta Obstet Gynecol Scand Suppl 101 (1981) 71-74
55. Camaggi C.M., Strocchi E., Giovannini M., et al. Medroxyprogesterone acetate (MPA) plasma levels after multiple high-dose administration in advanced cancer patients. Cancer Chemother Pharmacol 11 (1983) 19-22
56. Antal E.J., Wright III C.E., Gillespie W.R., and Albert K.S. Influence of route of administration on the pharmacokinetics of medroxyprogesterone. J Pharmacokinet Biopharm 11 (1983) 561-576
57. Kobayashi K., Mimura N., Fujii H., et al. Role of human cytochrome P450 3A4 in metabolism of medroxyprogesterone acetate. Clin Cancer Res 6 (2000) 3297-3303
58. Blossey H.C., Bartsch H.H., Kanne D., et al. The pharmacokinetics of high-dose medroxyprogesterone acetate (MPA) in the therapy of advanced breast cancer. Cancer Chemother Pharmacol 8 (1982) 77-81
59. Stockdale A.D., Chapman D., Mould G.P., and Rostom A.Y. Medroxyprogesterone acetate: Variation in serum concentrations achieved with three commercially available preparations. Cancer Treat Rep 71 (1987) 813-815
60. Rautio A. Liver function and medroxyprogesterone acetate elimination in man. Biomed Pharmacother 38 (1984) 199-204
61. Lønning P.E., Lien E.A., Lundgren S., and Kvinnsland S. Clinical pharmacokinetics of endocrine agents used in advanced breast cancer. Clin Pharmacokinet 22 (1992) 327-358
62. Zhang J.W., Liu Y., Li W., et al. Inhibitory effects of medroxyprogesterone acetate on human liver cytochrome P450 enzymes. Eur J Clin Pharmacol 62 (2006) 497-502
63. Westhoff C., Jain J.K., Milsom I., and Ray A. Changes in weight with depot medroxyprogesterone acetate subcutaneous injection 104 mg/0.65 mL. Contraception 75 (2007) 261-267
64. Deen B.F., Shuler Jr. R.K., and Fekrat S. Retinal venous occlusion associated with depot medroxyprogesterone acetate. Br J Ophthalmol 91 (2007) 1254
65. Goldstein J., Cushman M., Badger G.J., and Johnson J.V. Effect of depomedroxyprogesterone acetate on coagulation parameters: A pilot study. Fertil Steril 87 (2007) 1267-1270
66. Anonymous. Leuprolide Acetate and Triptorelin Pamoate Monographs. AHFS Drug Information 2008 (2008), American Society of Health-System Pharmacists, Bethesda, Md 1136-1144 1257-1258
67. Lupron (leuprolide acetate suspension for injection and depot [3.75, 7.5, 11.25, 15, 22.5, and 30 mg] injection) [package insert] (2000-2005), TAP Pharmaceuticals, Lake Forest, Ill
68. Eligard (leuprolide acetate for injectable suspension [7.5, 22.5, 30, and 45 mg depot injections]) [package insert] (2006), Sanofi-Aventis, Bridgewater, NJ
69. Trelstar Depot 3.75 mg and Trelstar LA (triptorelin pamoate suspension for infection) [package insert] (2006), Walson Pharmaceuticals, Morristown, NJ
70. Anonymous. Triptorelin pamoate. Phase III Drug Profiles 3 (1993) 1-8
71. Geisthoevel F., Hils K., Wieacker P., et al. Monthly administration of the LH-RH analogue decapeptyl for longterm treatment of ovarian dysfunctions and estrogen-dependent disorders. Int J Fertil 34 (1989) 262-270
72. Müller F.O., Terblanche J., Schall R., et al. Pharmacokinetics of triptorelin after intravenous bolus administration in healthy males and in males with renal or hepatic insufficiency. Br J Clin Pharmacol 44 (1997) 335-341
73. Sennello L.T., Finley R.A., and Chu S.Y. Single-dose pharmacokinetics of leuprolide in humans following intravenous and subcutaneous administration. J Pharm Sci 75 (1986) 158-160
74. Potocnik F. Successful treatment of hypersexuality in AIDS dementia with cyproterone acetate. S Afr Med J 81 (1992) 433-434 Letter
75. Haussermann P., Goecker D., Beier K., and Schroeder S. Lowdose cyproterone acetate treatment of sexual acting out in men with dementia. Int Psychogeriatr 15 (2003) 181-186
76. Byrne A., Brunet B., and McGann P. Cyproterone acetate therapy and aggression. Br J Psychiatry 160 (1992) 282-283 Letter
77. Stewart J.T. Optimizing antilibidinal treatment with medroxyprogesterone acetate. J Am Geriatr Soc 53 (2005) 359-360 Letter
78. Cooper A.J. Medroxyprogesterone acetate as a treatment for sexual acting out in organic brain syndrome. Am J Psychiatry 145 (1988) 1179-1180 Letter
79. Light S.A., and Holroyd S. The use of medroxyprogesterone acetate for the treatment of sexually inappropriate behaviour in patients with dementia. J Psychiatry Neurosci 31 (2006) 132-134
80. Amadeo M. Antiandrogen treatment of aggressivity in men suffering from dementia. J Geriatr Psychiatry Neurol 9 (1996) 142-145
81. Cooper A.J. Medroxyprogesterone acetate (MPA) treatment of sexual acting out in men suffering from dementia. J Clin Psychiatry 48 (1987) 368-370
82. Weiner M.F., Denke M., Williams K., and Guzman R. Intramuscular medroxyprogesterone acetate for sexual aggression in elderly men. Lancet 339 (1992) 1121-1122 Letter
83. Kay P., Yurkow J., Forman L.J., et al. Transdermal estradiol in the management of aggressive behaviors in male patients with dementia. Clin Gerontol 15 (1995) 54-58
84. Shelton P.S., and Brooks V.G. Estrogen for dementia-related aggression in elderly men. Ann Pharmacother 33 (1999) 808-812
85. Kyomen H.H., Nobel K.W., and Wei J.Y. The use of estrogen to decrease aggressive physical behavior in elderly men with dementia. J Am Geriatr Soc 39 (1991) 1110-1112
86. Rosenthal M., Berkman P., Shapira A., et al. Urethral masturbation and sexual disinhibition in dementia: A case report. Isr J Psychiatry Relat Sci 40 (2003) 67-72
87. MacKnight C., and Rojas-Fernandez C. Quetiapine for sexually inappropriate behavior in dementia. J Am Geriatr Soc 48 (2000) 707 Letter
88. Stewart J.T., and Shin K.J. Paroxetine treatment of sexual disinhibition in dementia. Am J Psychiatry 154 (1997) 1474 Letter
89. Leo R.J., and Kim K.Y. Clomipramine treatment of paraphilias in elderly demented patients. J Geriatr Psychiatry Neurol 8 (1995) 123-124
90. Simpson D.M., and Foster D. Improvement in organically disturbed behavior with trazodone treatment. J Clin Psychiatry 47 (1986) 191-193
91. Tiller J.W.G., Dakis J.A., and Shaw J.M. Short-term buspirone treatment in disinhibition with dementia. Lancet 2 (1998) 510 Letter
92. Jensen C.F. Hypersexual agitation in Alzheimer's disease. J Am Geriatr Soc 37 (1989) 917 Letter
93. Alkhalil C., Hahar N., Alkhalil B., et al. Can gabapentin be a safe alternative to hormonal therapy in the treatment of inappropriate sexual behavior in demented patients?. Int Urol Nephrol 35 (2003) 299-302
94. Freymann N., Michael R., Dodel R., and Jessen F. Successful treatment of sexual disinhibition in dementia with carbamazepine\3-a case report. Pharmacopsychiatry 38 (2005) 144-145
95. Alagiakrishnan K., Sclater A., and Robertson D. Role of cholinesterase inhibitor in the management of sexual aggression in an elderly demented woman. J Am Geriatr Soc 51 (2003) 1326 Letter
96. Wiseman S.V., McAuley J.W., Freidenberg G.R., and Freidenberg D.L. Hypersexuality in patients with dementia: Possible response to cimetidine. Neurology 54 (2000) 2024
97. Kyomen H.H., Satlin A., and Wei J.Y. Estrogen therapy decreases physically aggressive behaviors in elderly long-term care facility dementia patients: Results from a double-blind, placebo-controlled clinical trial. J Neuropsychiatry Clin Neurosci 9 (1997) 174 Abstract P151
98. Brantley J.T., and Wise T.N. Antiandrogenic treatment of a gender-dysphoric transvestite. J Sex Marital Ther 11 (1985) 109-112
99. Huertas D., López-Ibor Aliño J.J., Molina J.D., et al. Antiaggressive effect of cyproterone versus haloperidol in Alzheimer's disease: A randomized double-blind pilot study. J Clin Psychiatry 68 (2007) 439-444
100. Clayton A.H. Fetishism and clomipramine. Am J Psychiatry 150 (1993) 673-674 Letter
101. Ward T., Gannon T.A., and Birgden A. Human rights and the treatment of sex offenders. Sex Abuse 19 (2007) 195-216
102. Weinberger L.E., Sreenivasan S., Garrick T., and Osran H. The impact of surgical castration on sexual recidivism risk among sexually violent predatory offenders. J Am Acad Psychiatry Law 33 (2005) 16-36